Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Pharmacokinetics of Continuous Infusion Therapy of Factor VIII Concentrates in Hemophilia A Patients with Inhibitors,

Katsumi Nishiya, MD, PhD, Ichiro Tanaka, MD, PhD, Keiji Nogami, MD, PhD, Kenichi Ogiwara, MD, PhD, Koji Yada, MD, Tomoko Matsumoto, Midori Shima, MD, PhD

Blood (2011) 118 (21): 3320.

https://doi.org/10.1182/blood.V118.21.3320.3320

Published: 2011

Journal Articles

Tissue Factor Pathway Inhibitor Causes Unresponsiveness to Activated Prothrombin Complex Concentrates for Hemophilia A Patients with Inhibitors.

Kenichi Ogiwara, MD, Keiji Nogami, MD, PhD, Ichiro Tanaka, MD, PhD, Katsumi Nishiya, MD, PhD, Nobuyuki Tsujii, MD, Midori Shima, MD, PhD

Blood (2010) 116 (21): 3663.

https://doi.org/10.1182/blood.V116.21.3663.3663

Published: 2010

Journal Articles

Localization of Factor VIII Interactive Site within Plasmin/Plasminogen Which Is Responsible for Plasmin-Catalyzed Activation/Inactivation of Factor VIII.

Katsumi Nishiya, MD, Keiji Nogami, M.D., Kiyotaka Okada, M.D., Osamu Matsuo, M.D., Masahiro Takeyama, M.D., Kenichi Ogiwara, M.D., Ichiro Tanaka, M.D., Akira Yoshioka, M.D., Midori Shima, M.D.

Blood (2007) 110 (11): 1759.

https://doi.org/10.1182/blood.V110.11.1759.1759

Published: 2007

Journal Articles

Identification of a Thrombin-Interactive Site within Factor VIII A2 Domain Responsible for the Cleavage at Arg372.

Keiji Nogami, MD, PhD, Midori Shima, MD,PhD, Evgueni L. Saenko, PhD, Masahiro Takeyama, MD, Kohei Tatsumi, MD, Yuri Fujita, MD, Ichiro Tanaka, MD,PhD, Akira Yoshioka, MD,PhD

Blood (2006) 108 (11): 1710.

https://doi.org/10.1182/blood.V108.11.1710.1710

Published: 2006

Journal Articles

Protein S Down-Regulates Factor VIIIa by Competing with Factor IXa.

Masahiro Takeyama, MD, Keiji Nogami, MD.PhD, Kohei Tatsumi, MD, Yuri Fujita, MD, Ichiro Tanaka, MD,PhD, Akira Yoshioka, MD,PhD, Midori Shima, MD,PhD

Blood (2006) 108 (11): 1714.

https://doi.org/10.1182/blood.V108.11.1714.1714

Published: 2006

Journal Articles

Characterization of an Anti-Factor VIII Monoclonal Antibody with A1 and A3 Epitopes Which Increases Factor VIII Activity.

Masahiro Takeyama, MD, Keiji Nogami, MD,PhD, Tetsuhiro Soeda, phD, Tsukasa Suzuki, phD, Kunihiro Hattori, phD, Kohei Tatsumi, MD, Yuri Fujita, MD, Ichiro Tanaka, MD.PhD, Akira Yoshioka, MD,PhD, Midori Shima, MD,PhD

Blood (2006) 108 (11): 1702.

https://doi.org/10.1182/blood.V108.11.1702.1702

Published: 2006

Journal Articles

Identification of a Plasmin-Interactive Site in the Factor VIII Light Chain Responsible for Proteolytic Cleavage at Lys36 in the A1 Domain.

Keiji Nogami, MD, PhD, Midori Shima, MD,PhD, Masahiro Takeyama, MD, Kohei Tatsumi, MD, Yuri Fujita, MD, Evgueni L. Saenko, PhD, Ichiro Tanaka, MD,PhD, Akira Yoshioka, MD,PhD

Blood (2006) 108 (11): 1709.

https://doi.org/10.1182/blood.V108.11.1709.1709

Published: 2006

Journal Articles

Mechanisms of Plasmin-Catalyzed Inactivation of the Factor VIII.

Keiji Nogami, MD, PhD, Midori Shima, MD, PhD, Tomoko Matsumoto, Katsumi Nishiya, MD, Masahiro Takeyama, MD, Kohei Tatsumi, MD, Ichiro Tanaka, MD, PhD, Akira Yoshioka, MD, PhD

Blood (2005) 106 (11): 1017.

https://doi.org/10.1182/blood.V106.11.1017.1017

Published: 2005

Journal Articles

Identification of a Plasmin-Interactive Site within the A2 Domain of the Factor VIII Heavy Chain.

Keiji Nogami, MD, PhD, Midori Shima, MD, PhD, Katsumi Nishiya, MD, Evgueni L. Saenko, PhD, Masahiro Takeyama, MD, Kohei Tatsumi, MD, Ichiro Tanaka, MD, PhD, Akira Yoshioka, MD, PhD

Blood (2005) 106 (11): 1018.

https://doi.org/10.1182/blood.V106.11.1018.1018

Published: 2005

Journal Articles

von Willebrand Factor Protects Ca 2+ -Dependent Structure of the Factor VIII Light Chain.

Masahiro Takeyama, MD, Midori Shima, MD, PhD, Keiji Nogami, MD, PhD, Masahiro Okuda, PhD, Yoshihiko Sakurai, MD, PhD, Kohei Tatsumi, MD, Tomohiro Takeda, Ichiro Tanaka, MD, PhD, Akira Yoshioka, MD, PhD

Blood (2005) 106 (11): 1008.

https://doi.org/10.1182/blood.V106.11.1008.1008

Published: 2005

Journal Articles

A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C–catalyzed inactivation

Keiji Nogami, Midori Shima, Katsumi Nishiya, Kazuya Hosokawa, Evgueni L. Saenko, Yoshihiko Sakurai, Masaru Shibata, Hiroshi Suzuki, Ichiro Tanaka, Akira Yoshioka

Blood (2002) 99 (11): 3993–3998.

https://doi.org/10.1182/blood.V99.11.3993

Published: 2002

Journal Articles

Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C–mediated proteolysis

Keiji Nogami, Midori Shima, John C. Giddings, Kazuya Hosokawa, Masanori Nagata, Seiki Kamisue, Hiroshi Suzuki, Masaru Shibata, Evgueni L. Saenko, Ichiro Tanaka, Akira Yoshioka

Blood (2001) 97 (3): 669–677.

https://doi.org/10.1182/blood.V97.3.669

Published: 2001

NARROW

Pharmacokinetics of Continuous Infusion Therapy of Factor VIII Concentrates in Hemophilia A Patients with Inhibitors,

Tissue Factor Pathway Inhibitor Causes Unresponsiveness to Activated Prothrombin Complex Concentrates for Hemophilia A Patients with Inhibitors.

Localization of Factor VIII Interactive Site within Plasmin/Plasminogen Which Is Responsible for Plasmin-Catalyzed Activation/Inactivation of Factor VIII.

Identification of a Thrombin-Interactive Site within Factor VIII A2 Domain Responsible for the Cleavage at Arg372.

Protein S Down-Regulates Factor VIIIa by Competing with Factor IXa.

Characterization of an Anti-Factor VIII Monoclonal Antibody with A1 and A3 Epitopes Which Increases Factor VIII Activity.

Identification of a Plasmin-Interactive Site in the Factor VIII Light Chain Responsible for Proteolytic Cleavage at Lys36 in the A1 Domain.

Mechanisms of Plasmin-Catalyzed Inactivation of the Factor VIII.

Identification of a Plasmin-Interactive Site within the A2 Domain of the Factor VIII Heavy Chain.

von Willebrand Factor Protects Ca 2+ -Dependent Structure of the Factor VIII Light Chain.

A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C–catalyzed inactivation

Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C–mediated proteolysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only